Publications by authors named "Jestinah Chevure"
Article Synopsis
- Pulmonary arterial hypertension (PAH) is a serious disease, and the STELLAR trial evaluated the effects of sotatercept combined with background therapy (BGT) compared to placebo with BGT.* -
- A Markov-type model was used to project long-term outcomes, showing that those receiving sotatercept plus BGT gained an average of 11.5 additional years of life expectancy and reduced hospitalizations and transplants compared to BGT alone.* -
- The study concluded that sotatercept significantly improves the life expectancy of PAH patients while decreasing the need for infused prostacyclin and reducing hospital stays, but real-world validation of these results is necessary.*
Introduction: Pembrolizumab was recently approved as an adjuvant treatment of renal cell carcinoma (RCC), based on prolonged disease-free survival compared to placebo in the phase III KEYNOTE-564 trial. The objective of this study was to evaluate the cost-effectiveness of pembrolizumab as monotherapy in the adjuvant treatment of RCC post-nephrectomy, from a US health sector perspective.
Patients And Methods: A Markov model with 4 health states (disease-free, locoregional recurrence, distant metastases, and death) was developed to compare the cost and effectiveness of pembrolizumab versus routine surveillance or sunitinib.